Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease

doi:10.4292/wjgpt.v17.i2.116608

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

(31)

(28)

(0)

(21)

(427)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 116608
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.116608

Table 3 Serum and fecal biomarkers investigated in the context of inflammatory bowel disease according to recent publications[46,116,117,121,122]

Serum biomarkers	Fecal (or colorectal mucus) biomarkers
C-reactive protein¹	Fecal calprotectin
Angiopoietin 1¹	Fecal lactoferrin
Angiopoietin 2¹	Fecal protein S100A12
Serum amyloid A1¹	Fecal protein - high mobility group 1
Interleukin 7¹	Neopterin
Extracellular matrix metalloproteinase inducer¹	Polymorphonuclear neutrophil elastase
Matrix metalloproteinase 1¹	Fecal hemoglobin
Matrix metalloproteinase 2¹	α1-antitrypsin
Matrix metalloproteinase 3¹	Human neutrophil peptides
Matrix metalloproteinase 9¹	Neutrophil gelatinase-associated lipocalin
Transforming growth factor α¹	Chitinase 3-like-1
Carcinoembryonic antigen-related cell adhesion molecule 1¹	Matrix metalloproteinase 9
Vascular cell adhesion molecule 1¹	Lysozyme
Serum calprotectin	M2-pyruvate kinase
Serum protein S100A12	Myeloperoxidase
Neopterin	Eosinophil cationic protein
Endothelin	Human β-defensin 2
Interleukin-6, interleukin-8, interleukin-17	β-glucuronidase
Soluble tumor necrosis factor receptor 1	Osteoprotegerin
Soluble interleukin-2 receptor	Lipocalin-2/neutrophil gelatinase-associated lipocalin
Perinuclear anti-neutrophil cytoplasmic antibodies	Colorectal mucus calprotectin
Anti-Saccharomyces cerevisiae antibodies	Colorectal mucus eosinophil-derived neurotoxin
Anti-mannobioside carbohydrate antibodies	MicroRNAs (MiR-16, MiR-21, MiR-223, MiR-1246)
Anti-laminaribioside carbohydrate antibodies
Anti-chitobioside carbohydrate antibodies
Anti-laminarin antibodies
Anti-chitin antibodies
Anti-flagellin CBir1 antibodies
Antibodies against the outer-membrane porin C of Escherichia coli
Antibodies against a Pseudomonas fluorescence-associated sequence l2
Serum leucine-rich glycoprotein
Micro RNAs (MiR-16, MiR-21, MiR-155, MiR-223, MiR-320a)

¹Components of Endoscopic Healing Index[118].

Full Size Table

Citation: Loktionov A. Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(2): 116608
URL: https://www.wjgnet.com/2150-5349/full/v17/i2/116608.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.116608

Loktionov A. Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2026; 17(2): 116608 [PMID: 42273247 DOI: 10.4292/wjgpt.v17.i2.116608]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.